DK1633883T3 - Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet - Google Patents

Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet

Info

Publication number
DK1633883T3
DK1633883T3 DK04742944T DK04742944T DK1633883T3 DK 1633883 T3 DK1633883 T3 DK 1633883T3 DK 04742944 T DK04742944 T DK 04742944T DK 04742944 T DK04742944 T DK 04742944T DK 1633883 T3 DK1633883 T3 DK 1633883T3
Authority
DK
Denmark
Prior art keywords
ampk
lkb1
analyzing
substrate kinase
phosphorylation
Prior art date
Application number
DK04742944T
Other languages
English (en)
Inventor
David Carling
Angela Woods
Fiona Leiper
Marian Carlson
Seung Hong
Original Assignee
Medical Res Council
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329866A external-priority patent/GB2402938B/en
Application filed by Medical Res Council, Univ Columbia filed Critical Medical Res Council
Application granted granted Critical
Publication of DK1633883T3 publication Critical patent/DK1633883T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
DK04742944T 2003-06-17 2004-06-17 Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet DK1633883T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47910003P 2003-06-17 2003-06-17
GB0329866A GB2402938B (en) 2003-06-17 2003-12-23 Kinase assay
PCT/GB2004/002584 WO2004113562A1 (en) 2003-06-17 2004-06-17 Method for assaying lkb1 phosphorylation activity

Publications (1)

Publication Number Publication Date
DK1633883T3 true DK1633883T3 (da) 2009-01-26

Family

ID=33542697

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04742944T DK1633883T3 (da) 2003-06-17 2004-06-17 Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet

Country Status (7)

Country Link
EP (1) EP1633883B1 (da)
JP (1) JP4651617B2 (da)
AT (1) ATE408023T1 (da)
DE (1) DE602004016503D1 (da)
DK (1) DK1633883T3 (da)
ES (1) ES2313029T3 (da)
WO (1) WO2004113562A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1651673B1 (en) * 2003-07-17 2008-04-16 University of Dundee Methods for use of an lkb1/strad/mo25 complex
US7439341B2 (en) 2003-11-14 2008-10-21 Integrated Dna Technologies, Inc. Fluorescence quenching azo dyes, their methods of preparation and use
CA2595564C (en) * 2005-02-16 2015-03-31 Md Bioalpha Co., Ltd. Use of .beta.-lapachone and related naphthoquinones in the treatment of amp-activated protein kinase (ampk) mediated disorders
AU2006251637B2 (en) * 2005-05-20 2012-06-14 Integrated Dna Technologies, Inc. Compounds and methods for labeling oligonucleotides
US8916345B2 (en) 2010-03-26 2014-12-23 Integrated Dna Technologies, Inc. Methods for enhancing nucleic acid hybridization
US9506057B2 (en) 2010-03-26 2016-11-29 Integrated Dna Technologies, Inc. Modifications for antisense compounds
WO2012033848A1 (en) 2010-09-07 2012-03-15 Integrated Dna Technologies, Inc. Modifications for antisense compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1036844A4 (en) * 1997-11-27 2002-12-04 Chugai Pharmaceutical Co Ltd Test methods, test reagent and remedies for diseases caused by changes in the LKB1 gene
WO2001093874A1 (en) * 2000-06-09 2001-12-13 Brigham Young University Method of treatment of obesity and paralyzed muscle and ergogenic aids

Also Published As

Publication number Publication date
JP4651617B2 (ja) 2011-03-16
EP1633883B1 (en) 2008-09-10
ES2313029T3 (es) 2009-03-01
JP2007520199A (ja) 2007-07-26
DE602004016503D1 (de) 2008-10-23
ATE408023T1 (de) 2008-09-15
WO2004113562A1 (en) 2004-12-29
EP1633883A1 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
BRPI0415210A (pt) compostos e composições como inibidores de proteìna cinase
BRPI0409173A (pt) compostos e composições como inibidores de proteìna quinase
WO2007030693A3 (en) Methods for promoting stem cell proliferation and survival
BRPI0607307A2 (pt) compostos e composições como inibidores de proteìna cinase
ATE497262T1 (de) Bipolare platte und ihre verwendung sowie verfahren für ihre herstellung und die bipolare platte enthaltendes elektrochemisches system
WO2007022268A3 (en) Compounds and compositions as protein kinase inhibitors
WO2004096148A3 (en) Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
ATE492228T1 (de) Knochenplatte
BRPI0815572A2 (pt) Compostos e composições como inibidores de quinases
WO2002000918A3 (de) Biosensor und herstellverfahren dafür
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2005111233A3 (en) Methods and kits to detect hereditary angioedema type iii
DK1633883T3 (da) Fremgangsmåde til analyse af LKB1-phosphoryleringsaktivitet
WO2007047754A3 (en) Mtor pathway theranostic
MX2010002004A (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa.
MX2009004141A (es) Composiciones y metodos para modular receptores de c-kit y pdgfr.
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
WO2008017002A3 (en) Polymorphisms in genes affecting cns disorders and uses thereof
WO2006001954A3 (en) Methods for promoting the formation of platelets and for treating blood and bone marrow disorders
DK1756571T3 (da) Fremgangsmåde i realtid til detektering af akut inflammatoriske tilstande
WO2003051302A3 (en) Methods and compositions for treatment of central nervous system disorders
NO20055025D0 (no) Multiplex screening for lysosomale lagringsforstyrrelser (LSD)
WO2007044622A8 (en) Use of mif and mif pathway agonists
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
WO2006076041A3 (en) Pan-her antagonists and methods of use